<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614016</url>
  </required_header>
  <id_info>
    <org_study_id>HQP 2007-001</org_study_id>
    <nct_id>NCT00614016</nct_id>
  </id_info>
  <brief_title>A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemaQuest Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HemaQuest Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety and pharmacokinetic study of a single dose of ST20 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 study in healthy volunteers to assess the safety and pharmacokinetics of ST20 after&#xD;
      oral administration of a single-dose. In addition, a comparison of the pharmacokinetics and&#xD;
      exposure of a single dose of ST20 under fasting and non-fasting conditions will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety, maximum tolerated dose</measure>
    <time_frame>specified timepoints in the protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>specified timepoints in the protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects total (6 active and 2 placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium ST20</intervention_name>
    <description>single administration of oral dosage form</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be a healthy male or female&#xD;
&#xD;
          -  Be between the ages of 18 and 45 years old, inclusive&#xD;
&#xD;
          -  Be able and willing to give informed consent&#xD;
&#xD;
          -  Be able to comply with all study procedures&#xD;
&#xD;
          -  If female, not be pregnant, including negative serum pregnancy test&#xD;
&#xD;
          -  If female, must not be of childbearing potential or must agree to use one or more of&#xD;
             the following forms of contraception during screening and throughout the study:&#xD;
             hormonal (i.e., oral, transdermal, implant or injection); double barrier (i.e.,&#xD;
             condom, diaphragm with spermicide); intrauterine device (IUD); vasectomized partner&#xD;
             (six months minimum); or abstinence. Male subjects must also agree to use one or more&#xD;
             of the above forms of birth control for either themselves or their partner, as&#xD;
             appropriate throughout the course of the study&#xD;
&#xD;
          -  Must not be receiving prescription medication within the 2 weeks before administration&#xD;
             of the test dose, except for multivitamins or contraception&#xD;
&#xD;
          -  Have white blood cell count, hemoglobin, hematocrit and platelet count within normal&#xD;
             range for the testing facility&#xD;
&#xD;
          -  Must have serum chemistry values and urinalysis values within the limits of normal for&#xD;
             the testing facility&#xD;
&#xD;
          -  Must have coagulation parameters within the limits of normal for the testing facility&#xD;
&#xD;
          -  Must have a negative urine test for substances of abuse including marijuana, cocaine,&#xD;
             cocaine derivatives, opiates and methadone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have clinically significant vital signs&#xD;
&#xD;
          -  Have any clinically significant laboratory value (CBC, serum chemistry, or urinalysis)&#xD;
&#xD;
          -  Have made a blood donation of 500mL within the 2 months before administration of study&#xD;
             medication&#xD;
&#xD;
          -  Have received a blood transfusion within the 3 months before administration of study&#xD;
             medication&#xD;
&#xD;
          -  Have an acute febrile illness or upper respiratory tract illness within 72 hours prior&#xD;
             to administration of study medication&#xD;
&#xD;
          -  Have received another investigational agent within the 4 weeks before administration&#xD;
             of test drug&#xD;
&#xD;
          -  Have received any other investigational agent during this study&#xD;
&#xD;
          -  Have any acute or chronic disease (e.g., history of hepatitis or HIV-1)&#xD;
&#xD;
          -  Have cardiac disease including congestive heart failure or arrhythmia&#xD;
&#xD;
          -  Have a history of central nervous system disease, such as seizures&#xD;
&#xD;
          -  Be breast feeding a child&#xD;
&#xD;
          -  Have been a smoker in the past 12 months&#xD;
&#xD;
          -  Have Body Mass Index (BMI) &gt; 33 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Downey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles River Clinical Services Northwest, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles River Clinical Services Northwest, Inc.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>August 1, 2008</last_update_submitted>
  <last_update_submitted_qc>August 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Susan Perrine, MD/ Chief Scientific Officer</name_title>
    <organization>HemaQuest Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

